AI mapping technology outperforms MRI in predicting prostate cancer spread, study shows

City of Hope deploys HopeLLM: AI platform transforms clinical workflows and patient care

City of Hope has developed and deployed HopeLLM, a proprietary generative AI platform that addresses critical operational challenges in hospitals while advancing personalized cancer care.

CancerLinQ receives ASCO-certified RQS status

Concert AI’s CancerLinQ initiative has received ASCO’s Recognized Quality Solution status—a recognition that positions the platform as a validated gateway for partnered oncology practices into ASCO’s flagship certification program.

September 05, 2025

Vol.51 No.32

Clinical Roundup

Decipher Prostate Test predicts chemo benefit in metastatic prostate cancer, phase III trial shows

The Decipher Prostate Genomic Classifier predicts which patients with metastatic cancer are likely to benefit from treatment intensification with the chemotherapy docetaxel and which are not likely to benefit and can therefore avoid unnecessary toxicity, according to findings by University College London and Veracyte, Inc., a genomic diagnostic company.

September 05, 2025

Vol.51 No.32

In Brief

UIC, Northwestern, Moffitt researchers awarded $1.2M DOD grant for prostate cancer research

The U.S. Department of Defense Prostate Cancer Research Program has awarded the Data Science Award and a $1.2 million grant to researchers Charles Gaber, Natalie Reizine, Todd Lee, Lucia Petito, and Jessica Islam.

August 01, 2025

Vol.51 No.30

Clinical Roundup

Tumor-infiltrating clonal hematopoiesis findings validated by AI analysis

Tumor-infiltrating clonal hematopoiesis is prevalent across solid tumors with the highest incidence in non-small cell lung cancer and results in a higher rate of mortality, according to a study by Caris Life Sciences that independently validates recent findings on TI-CH.

July 25, 2025

Vol.51 No.29

Imaging’s ride to the bottom in clinical trials—and why it matters now

In cancer care, imaging has become a marvel of modern medicine. Advances in scanner technology, reconstruction algorithms, contrast agents, and diagnostic protocols have radically improved our ability to detect, track, and understand disease. Clinically, imaging is fast, accurate, and central to decision-making.

July 18, 2025

Vol.51 No.28

By Jeff Sorenson

AI mapping technology outperforms MRI in predicting prostate cancer spread, study shows

YOU MAY BE INTERESTED IN

City of Hope deploys HopeLLM: AI platform transforms clinical workflows and patient care

CancerLinQ receives ASCO-certified RQS status

Decipher Prostate Test predicts chemo benefit in metastatic prostate cancer, phase III trial shows

UIC, Northwestern, Moffitt researchers awarded $1.2M DOD grant for prostate cancer research

Tumor-infiltrating clonal hematopoiesis findings validated by AI analysis

Imaging’s ride to the bottom in clinical trials—and why it matters now

Renew today!

Subscriber content

Never miss an issue!

Login